144 related articles for article (PubMed ID: 16444378)
1. [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?].
Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K
Arq Gastroenterol; 2005; 42(4):233-8. PubMed ID: 16444378
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.
Giménez A; Minguela A; Parrilla P; Bermejo J; Pérez D; Molina J; García AM; Ortiz MA; Alvarez R; de Haro LM
Cancer; 1998 Aug; 83(4):641-51. PubMed ID: 9708926
[TBL] [Abstract][Full Text] [Related]
3. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
4. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
Younes M; Lebovitz RM; Lechago LV; Lechago J
Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
[TBL] [Abstract][Full Text] [Related]
5. Time gated fluorescence spectroscopy in Barrett's oesophagus.
Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
7. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
9. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.
Symmans PJ; Linehan JM; Brito MJ; Filipe MI
J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model.
Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S
J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062
[TBL] [Abstract][Full Text] [Related]
11. p53 and Ki-67 in Barrett's carcinoma: is there any value to predict recurrence after circumferential endoscopic mucosal resection?
Lopes CV; Mnif H; Pesenti C; Bories E; Monges G; Giovannini M
Arq Gastroenterol; 2007; 44(4):304-8. PubMed ID: 18317648
[TBL] [Abstract][Full Text] [Related]
12. Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia.
Saeian K; Staff DM; Vasilopoulos S; Townsend WF; Almagro UA; Komorowski RA; Choi H; Shaker R
Gastrointest Endosc; 2002 Oct; 56(4):472-8. PubMed ID: 12297760
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination.
Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M
Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041
[TBL] [Abstract][Full Text] [Related]
14. [Dysplasia in Barrett's esophagus--intra- and interobserver variability in histopathological diagnosis].
Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K
Arq Gastroenterol; 2004; 41(2):79-83. PubMed ID: 15543378
[TBL] [Abstract][Full Text] [Related]
15. A comparative cytopathologic and histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus.
Geisinger KR; Teot LA; Richter JE
Cancer; 1992 Jan; 69(1):8-16. PubMed ID: 1727677
[TBL] [Abstract][Full Text] [Related]
16. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.
Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K
Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
18. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
19. Methylene blue chromoendoscopy for the detection of Barrett's esophagus in a Greek cohort.
Kouklakis GS; Kountouras J; Dokas SM; Molyvas EJ; Vourvoulakis GP; Minopoulos GI
Endoscopy; 2003 May; 35(5):383-7. PubMed ID: 12701007
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
